ID: PMRREP27310| 198 Pages | 10 Dec 2025 | Format: PDF, Excel, PPT* | Healthcare
The global circadian rhythm sleep treatment market size is valued at US$ 2.4 billion in 2025 and is projected to reach US$ 3.7 billion by 2032, growing at a CAGR of 6.5% between 2025 and 2032.
Circadian rhythm sleep-wake disorders (CRSWDs) are characterized by disruptions in the natural sleep-wake cycle, often caused by misalignment between the internal biological clock and external environmental cues. The growing prevalence of sleep disorders, coupled with increasingly irregular lifestyles and work schedules, is driving demand for effective circadian rhythm sleep treatments.
In addition, advancements in therapeutic devices, including wearable monitors and non-invasive interventions, alongside the adoption of targeted pharmacological therapies, are fueling market expansion. These factors position the global circadian rhythm sleep treatment market for sustained growth, with technology and innovation playing a central role in shaping treatment strategies.
| Key Insights | Details |
|---|---|
| Circadian Rhythm Sleep Treatment Market Size (2025E) | US$2.4 Billion |
| Market Value Forecast (2032F) | US$3.7 Billion |
| Projected Growth (CAGR 2025 to 2032) | 6.5% |
| Historical Market Growth (CAGR 2019 to 2024) | 5.5% |
The global circadian rhythm sleep treatment market is experiencing strong growth due to the rising prevalence of sleep disorders, including Delayed Sleep Phase Syndrome, Advanced Sleep Phase Syndrome, and Non-24-hour sleep-wake syndrome (N24).
Growing awareness of the consequences of disrupted sleep, such as increased risk of fatal accidents, further fuels demand. Globally, road fatalities are projected to double to 2.3 million, with 230,000-345,000 deaths attributed to drowsiness or exhaustion, while workplace accidents are also linked to insufficient sleep, emphasizing the need for effective interventions.
Advancements in therapy devices and the adoption of targeted pharmacological treatments are key market drivers. In March 2024, Vanda Pharmaceuticals received a patent for using the melatonin agonist to treat circadian rhythm disorders, including in blind patients, marking a significant step forward in circadian-targeted therapy. Such innovations enable clinicians to offer more effective management options for patients with complex sleep disorders.
The combination of growing prevalence, increasing public and clinical awareness, and the development of specialized therapies is expected to sustain robust growth in the global circadian rhythm sleep treatment market in the coming years.
The growth of the global circadian rhythm sleep treatment market may be restrained by several factors. A primary challenge is the lack of awareness about circadian rhythm sleep disorders (CRSDs) in underdeveloped and low-income regions, where many individuals remain undiagnosed or untreated. Limited understanding of the health risks associated with disrupted sleep can reduce treatment adoption, slowing market expansion.
Additionally, concerns over drug side effects and long-term safety may deter patients from initiating or continuing pharmacological therapies, particularly in regions with limited healthcare guidance. High treatment costs and limited access to specialized therapy devices, such as digital sleep solutions or wearable monitoring systems, further constrain market growth.
Moreover, cultural attitudes and sleep health priorities vary widely, creating disparities in demand across regions. Collectively, these factors could impede the widespread adoption of circadian rhythm sleep treatments despite rising prevalence and technological advancements.
The global circadian rhythm sleep treatment market presents substantial growth opportunities driven by the increasing integration of digital health technologies. Innovations such as wearable devices, mobile applications, remote monitoring tools, and AI-powered analytics are enabling more precise tracking and management of circadian disorders.
Over the past decade, research using wearable devices to study circadian patterns has expanded significantly, reflecting both growing clinical interest and consumer adoption.
Recent product launches highlight market potential for technology-driven solutions. In October 2024, Neurovalens introduced Modius Sleep, an FDA-cleared, non-invasive head-worn device for chronic insomnia. Used at home for 30 minutes nightly, it delivers mild vestibular nerve stimulation to regulate sleep and circadian rhythms, with clinical trials reporting improved sleep in 95% of participants.
These advancements demonstrate the opportunity for scalable, patient-friendly, and home-based interventions, supporting broader market expansion. Increasing consumer awareness, combined with digital and AI-enabled solutions, is expected to further accelerate adoption and innovation in circadian rhythm sleep treatments worldwide.
Devices account for a leading 68.2% share of the global circadian rhythm sleep treatment market in 2025. The dominance is driven by growing consumer preference for non-invasive, technology-based interventions, including wearable sleep monitors, head-worn devices, and light therapy equipment.
Advancements in AI, mobile applications, and remote monitoring tools further enhance the functionality and effectiveness of these devices, encouraging wider adoption. Increased awareness of circadian rhythm disorders and the need for real-time, home-based management solutions continue to support strong market growth for therapeutic devices.
Delayed Sleep Phase Syndrome (DSPS) is projected to dominate the global circadian rhythm sleep treatment market in 2025, capturing nearly 32.7% of the total share. Its high prevalence among adolescents and young adults, coupled with growing recognition of its impact on productivity and mental health, is driving treatment demand.
Non-24-hour sleep-wake disorder (N24), affecting primarily blind individuals but also some sighted people, is expected to grow the fastest due to increasing awareness and diagnostic improvements. Effective management of these disorders is becoming a key focus for healthcare providers.
Retail sales are projected to capture nearly 55.7% of the global market in 2025. The dominance of retail is driven by the convenience and accessibility of home-use sleep devices, wearable monitors, and over-the-counter products, enabling consumers to manage circadian rhythm disorders without frequent clinical visits.
Online and offline retail channels, including pharmacies and specialty stores, facilitate rapid product adoption. Rising consumer awareness, coupled with growing trust in self-monitoring and digital health technologies, continues to reinforce retail as the preferred channel for circadian rhythm sleep treatments globally.
By 2025, North America is projected to account for nearly 44.2% of the global circadian rhythm sleep treatment market, fueled by the high prevalence of sleep disorders and increasing adoption of digital health tools, including apps, wearables, and light therapy.
The American Academy of Sleep Disorders notes that the delayed sleep phase disorder is the most common CRSWD, affecting approximately 0.17% of the U.S. population and 7-16% of adolescents, with some studies suggesting a potential genetic link. CRSWDs are also prominent in individuals with bipolar disorder: during manic phases, 69-99% report reduced sleep, while 38-78% experience excessive sleepiness during depressive phases.
According to the National Institutes of Health, one in three U.S. adults does not get enough sleep, a trend worsening over time. The 2024 National Sleep Foundation poll indicated that nearly two-thirds of adults report insufficient sleep, with 57% believing longer sleep would improve their wellbeing. Women are particularly affected, with 64% reporting inadequate sleep compared to 52% of men.
In total, 50-70 million Americans have diagnosed sleep disorders such as obstructive sleep apnea (OSA), insomnia, restless leg syndrome (RLS), central disorders of hypersomnolence, or CRSWDs. Surveys estimate that up to 3% of adults have CRSWDs, but the actual prevalence may reach 10% in adults and 16% in teenagers.
Overall, these trends underscore a growing demand for effective circadian rhythm sleep treatments and supportive digital health solutions across North America.
By 2025, Europe is projected to hold nearly 24.4% of the global circadian rhythm sleep treatment market, driven by government-backed sleep health and chronobiology research initiatives, as well as growing demand for non-pharmacological therapies such as light therapy and cognitive behavioral therapy for insomnia (CBT-i).
Insomnia is a major health concern, affecting up to 50% of primary care patients either independently or comorbidly, which can exacerbate other medical conditions if left untreated.
Chronic insomnia, or insomnia disorder, has an estimated prevalence of 9-15% based on DSM (Diagnostic and Statistical Manual of Mental Disorders) and ICSD (International Classification of Sleep Disorders) criteria, and 85% of patients with mood disorders experience insomnia during depressive phases, with over half retaining symptoms even after remission.
The European Insomnia Guideline recommends CBT-i as the first-line treatment, with multicomponent strongly advised. Studies indicate 70-80% of patients respond positively, around 50% achieve meaningful symptom reduction, and approximately 40% reach remission, often sustained at six-month follow-ups.
These statistics, combined with increasing awareness of sleep health and the adoption of evidence-based non-pharmacological therapies across the region, highlight Europe’s strong focus on effective circadian rhythm sleep treatments, supporting sustained growth in the market.
The Asia Pacific circadian rhythm sleep treatment market is expanding rapidly, projected to grow at a CAGR of 8.0% over the forecast period.
Key drivers include growing awareness of sleep health and circadian rhythm sleep disorders (CRSD) among young professionals, alongside increasing adoption of digital sleep solutions such as apps and wearables in tech-savvy populations. Rising urbanization, irregular work hours, and lifestyle-induced sleep disruptions are further fueling demand for effective circadian rhythm interventions.
In September 2024, Australian company Re-Time launched its Retimer 3 smart wearable via Kickstarter. Developed with over 25 years of research at Flinders University, the device helps users monitor and align their circadian rhythm using precise blue-green light therapy.
Following its debut at the World Sleep Congress, it was showcased at Arab Health in Dubai and the Health Optimization Summit in London, highlighting growing regional interest in digital sleep solutions.
Later in December 2024, Monash University initiated the Australia-India Sleep Health Collaborative Initiative, connecting researchers and clinicians to improve sleep health, establish sleep medicine clinics in India, and explore innovative care models integrating modern and Ayurvedic practices.
These developments underscore the APAC market’s shift toward both technology-driven and collaborative approaches, supporting sustained growth in circadian rhythm sleep treatments.
The circadian rhythm sleep treatment industry is highly dynamic and rapidly evolving, driven by significant investments and innovation in digital and AI-enabled sleep solutions.
Companies are focusing on strategic growth initiatives, including funding rounds, partnerships, and technology development, to enhance product offerings, expand geographic reach, and accelerate market adoption. The competitive environment is shaped by a combination of technological advancements and increasing consumer demand, making strategic investments and collaborations critical for gaining market share and sustaining long-term growth.
The global circadian rhythm sleep treatment market is valued at US$ 2.4 Billion in 2025.
Rising prevalence of sleep disorders, lifestyle changes, and advancements in devices and therapies drive market growth.
The global circadian rhythm sleep treatment market is poised to witness a CAGR of 6.5% between 2025 and 2032.
Integration of digital health, AI-enabled devices, and home-based treatments presents major market opportunities.
Major players in the global Compumedics Limited, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., ResMed, and others.
| Report Attribute | Details |
|---|---|
| Historical Data/Actuals | 2019 - 2024 |
| Forecast Period | 2025 - 2032 |
| Market Analysis | Value: US$ Bn |
| Geographical Coverage |
|
| Segmental Coverage |
|
| Competitive Analysis |
|
| Report Highlights |
|
By Treatment
By Disorder
By Sales Channel
By Region
Delivery Timelines
For more information on this report and its delivery timelines please get in touch with our sales team.
About Author
